Immunization is the best strategy to protect individuals from influenza; however, older adults tend to respond less favorably to vaccines because of immunosenescence. The Centers for Disease Control and Prevention states that any licensed, recommended, and age-appropriate influenza vaccine may be used in older adults despite reasonable evidence suggesting that the high-dose and, to a lesser extent, the adjuvanted and recombinant influenza vaccines provide better protection than the standard-dose vaccines in this vulnerable population. In this era of precision medicine, clinicians can preferentially recommend these contemporary vaccines to equip their older patients with the best possible protection against influenza.
KimHWebsterRGWebbyRJ.Influenza virus: dealing with a drifting and shifting pathogen [published online January 26, 2018]. Viral Immunol. doi:10.1089/vim.2017.0141
2.
SoemaCKompierRAmorijJPKerstenGF.Current and next generation influenza vaccines: formulation and protection strategies. Eur J Pharm Biopharm. 2015;94:251-263. doi:10.1016/j.ejpb.2015.05.023
3.
TreanorJJ.Clinical practice: influenza vaccination. N Engl J Med. 2016;375:1261-1268. doi:10.1056/NEJMcp1512870
4.
Centers for Disease Control and Prevention. Weekly U.S. influenza surveillance report. https://www.cdc.gov/flu/weekly/. Accessed March 29, 2018.
5.
GrohskopfLASokolowLZBroderKR, et al.. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2017-18 influenza season. MMWR Recomm Rep. 2017;66(2):1-20. doi:10.15585/mmwr.rr6602a1
6.
Centers for Disease Control and Prevention, National Center for Health Statistics. Vaccination coverage among adults aged 65 and over: United States, 2015. https://www.cdc.gov/nchs/products/databriefs/db281.htm. Accessed March 29, 2018.
Mosterin HoppingAMcElhaneyJFonvilleJMPowersDCBeyerWEPSmithDJ.The confounded effects of age and exposure history in response to influenza vaccination. Vaccine. 2016;34:540-546. doi:10.1016/j.vaccine.2015.11.058
9.
Centers for Disease Control and Prevention. What you should know and do this flu season if you are 65 years and older. https://www.cdc.gov/flu/about/disease/65over.htm. Accessed February 26, 2018.
10.
DiazGranadosCADunningAJKimmelM, et al.. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635-645. doi:10.1056/NEJMoa1315727
11.
FalseyARTreanorJJTornieporthNCapellanJGorseGJ.Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172-180. doi:10.1086/599790
12.
DiazGranadosCADunningAJJordanovELandolfiVDenisMTalbotHK.High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine. 2013;31:861-866. doi:10.1016/j.vaccine.2012.12.013
13.
NaceDALinCJRossTMSaraccoSChurillaRMZimmermanRK.Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis. 2015;211:1915-1924. doi:10.1093/infdis/jiu622
14.
Young-XuYVan AalstRMahmudSM, et al.. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients [published online February 14, 2018]. J Infect Dis. doi:10.1093/infdis/jiy088
15.
ShayDKChillarigeYKelmanJ, et al.. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis. 2017;215:510-517. doi:10.1093/infdis/jiw641
16.
RichardsonDMMedvedevaELRobertsCBLinkinDR; Centers for Disease Control and Prevention Epicenter Program. Comparative effectiveness of high-dose versus standard dose influenza vaccination in community dwelling veterans. Clin Infect Dis. 2015;61:171-176. doi:10.1093/cid/civ261
17.
IzurietaHSThadaniNShayDK, et al.. Comparative effectiveness of high-dose versus standard dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis. 2015;15:293-300. doi:10.1016/S1473-3099(14)71087-4
18.
FreySEReyesMRReynalesH, et al.. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. 2014;32:5027-5034. doi:10.1016/j.vaccine.2014.07.013
19.
Van BuynderPGKonradSVan BuynderJL, et al.. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013;31:6122-6128. doi:10.1016/j.vaccine.2013.07.059
20.
BaxterRPatriarcaPAEnsorKIziksonRGoldenthalKLCoxMM.Evaluation of the safety, reactogenicity and immunogenicity of Flublok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011;29:2272-2278. doi:10.1016/j.vaccine.2011.01.039
21.
KeitelWATreanorJJEl SahlyHM, et al.. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons ≥65 years old. Vaccine. 2009;28:379-385. doi:10.1016/j.vaccine.2009.10.037
22.
DunkleLMIziksonRPatriarcaP, et al; PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376:2427-2436. doi:10.1056/NEJMoa1608862
23.
RaviottaJMSmithKJDePasseJ, et al.. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults. Vaccine. 2017;35:5708-5713. doi:10.1016/j.vaccine.2017.07.069
24.
RaviottaJMSmithKJDePasseJ, et al.. Cost-effectiveness and public health effect of influenza vaccine strategies for U.S. elderly adultsJ Am Geriatr Soc. 2016;64:2126-2131. doi:10.1111/jgs.14323
25.
ChitABeckerDLDiazGranadosCAMaschioMYauEDrummondM.Cost-effectiveness of high-dose versus standard dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomized controlled trial. Lancet Infect Dis. 2015;15:1459-1466. doi:10.1016/S1473-3099(15)00249-2
